Literature DB >> 10456936

beta-Chemokines enhance parasite uptake and promote nitric oxide-dependent microbiostatic activity in murine inflammatory macrophages infected with Trypanosoma cruzi.

J C Aliberti1, F S Machado, J T Souto, A P Campanelli, M M Teixeira, R T Gazzinelli, J S Silva.   

Abstract

In the present study, we describe the ability of Trypanosoma cruzi trypomastigotes to stimulate the synthesis of beta-chemokines by macrophages. In vivo infection with T. cruzi led to MIP-1alpha, RANTES, and JE/MCP1 mRNA expression by cells from peritoneal inflammatory exudate. In addition, in vitro infection with T. cruzi resulted in expression of beta-chemokine MIP-1alpha, MIP-1beta, RANTES, and JE mRNA by macrophages. The expression of the beta-chemokine MIP-1alpha, MIP-1beta, RANTES, and JE proteins by murine macrophages cultured with trypomastigote forms of T. cruzi was confirmed by immunocytochemistry. Interestingly, macrophage infection with T. cruzi also resulted in NO production, which we found to be mediated mainly by beta-chemokines. Hence, treatment with anti-beta-chemokine-specific neutralizing antibodies partially inhibited NO release by macrophages incubated with T. cruzi parasites. Further, the addition of the exogenous beta-chemokines MIP-1alpha, MIP-1beta, RANTES, and JE/MCP-1 induced an increased T. cruzi uptake, leading to enhanced NO production and control of parasite replication in a dose-dependent manner. L-NMMA, a specific inhibitor of the L-arginine-NO pathway, caused a decrease in NO production and parasite killing when added to cultures of macrophages stimulated with beta-chemokines. Among the beta-chemokines tested, JE was more potent in inhibiting parasite growth, although it was much less efficient than gamma interferon (IFN-gamma). Nevertheless, JE potentiates parasite killing by macrophages incubated with low doses of IFN-gamma. Together, these results suggest that in addition to their chemotactic activity, murine beta-chemokines may also contribute to enhancing parasite uptake and promoting control of parasite replication in macrophages and may play a role in resistance to T. cruzi infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10456936      PMCID: PMC96814     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro.

Authors:  D D Taub; S M Turcovski-Corrales; M L Key; D L Longo; W J Murphy
Journal:  J Immunol       Date:  1996-03-15       Impact factor: 5.422

Review 2.  Chemokines: progress toward identifying molecular targets for therapeutic agents.

Authors:  O M Howard; A Ben-Baruch; J J Oppenheim
Journal:  Trends Biotechnol       Date:  1996-02       Impact factor: 19.536

3.  Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes.

Authors:  J C Aliberti; M A Cardoso; G A Martins; R T Gazzinelli; L Q Vieira; J S Silva
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

4.  Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages.

Authors:  J S Silva; G N Vespa; M A Cardoso; J C Aliberti; F Q Cunha
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

5.  A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans.

Authors:  J A Lovchik; C R Lyons; M F Lipscomb
Journal:  Am J Respir Cell Mol Biol       Date:  1995-07       Impact factor: 6.914

6.  Mechanisms of myocardial damage in Trypanosoma cruzi infection.

Authors:  Z A Andrade
Journal:  Ciba Found Symp       Date:  1983

7.  Lymphotactin: a cytokine that represents a new class of chemokine.

Authors:  G S Kelner; J Kennedy; K B Bacon; S Kleyensteuber; D A Largaespada; N A Jenkins; N G Copeland; J F Bazan; K W Moore; T J Schall
Journal:  Science       Date:  1994-11-25       Impact factor: 47.728

8.  Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin 10: role of NK cells.

Authors:  F Cardillo; J C Voltarelli; S G Reed; J S Silva
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

9.  Requirement of MIP-1 alpha for an inflammatory response to viral infection.

Authors:  D N Cook; M A Beck; T M Coffman; S L Kirby; J F Sheridan; I B Pragnell; O Smithies
Journal:  Science       Date:  1995-09-15       Impact factor: 47.728

10.  CC chemokines induce the generation of killer cells from CD56+ cells.

Authors:  A A Maghazachi; A Al-Aoukaty; T J Schall
Journal:  Eur J Immunol       Date:  1996-02       Impact factor: 5.532

View more
  42 in total

1.  Stage-dependent role of nitric oxide in control of Trypanosoma cruzi infection.

Authors:  M Saeftel; B Fleischer; A Hoerauf
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Role of CCL3/MIP-1alpha and CCL5/RANTES during acute Trypanosoma cruzi infection in rats.

Authors:  Ester Roffê; Fabiano Oliveira; Adriano L S Souza; Vanessa Pinho; Danielle G Souza; Patrícia R S Souza; Remo C Russo; Helton C Santiago; Alvaro J Romanha; Herbert B Tanowitz; Jesus G Valenzuela; Mauro M Teixeira
Journal:  Microbes Infect       Date:  2010-05-07       Impact factor: 2.700

3.  The chemokines CXCL9 and CXCL10 promote a protective immune response but do not contribute to cardiac inflammation following infection with Trypanosoma cruzi.

Authors:  Jenny L Hardison; Ruth A Wrightsman; Philip M Carpenter; Thomas E Lane; Jerry E Manning
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

4.  The CC chemokine receptor 5 is important in control of parasite replication and acute cardiac inflammation following infection with Trypanosoma cruzi.

Authors:  Jenny L Hardison; Ruth A Wrightsman; Philip M Carpenter; William A Kuziel; Thomas E Lane; Jerry E Manning
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

5.  Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients.

Authors:  Juliana A S Gomes; Lilian M G Bahia-Oliveira; Manoel Otávio C Rocha; Solange C U Busek; Mauro M Teixeira; João Santana Silva; Rodrigo Correa-Oliveira
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

6.  Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation.

Authors:  Nicole L Sullivan; Christopher S Eickhoff; Xiuli Zhang; Olivia K Giddings; Thomas E Lane; Daniel F Hoft
Journal:  J Immunol       Date:  2011-06-29       Impact factor: 5.422

7.  Nitric oxide synthase-2 modulates chemokine production by Trypanosoma cruzi-infected cardiac myocytes.

Authors:  Fabiana S Machado; Janeusa T Souto; Marcos A Rossi; Lisia Esper; Herbert B Tanowitz; Julio Aliberti; João S Silva
Journal:  Microbes Infect       Date:  2008-10-08       Impact factor: 2.700

8.  Expression of cytokines and chemokines and microvasculature alterations of the tongue from patients with chronic Chagas' disease.

Authors:  Sanivia A de Lima Pereira; Viviane O Severino; Narayane L M Kohl; Denise B R Rodrigues; Polyanna M Alves; Juliana T Clemente-Napimoga; Marlene A dos Reis; Vicente P A Teixeira; Marcelo H Napimoga
Journal:  Parasitol Res       Date:  2009-06-10       Impact factor: 2.289

9.  A magnetic resonance imaging study of intestinal dilation in Trypanosoma cruzi-infected mice deficient in nitric oxide synthase.

Authors:  Lars Ny; Hua Li; Shankar Mukherjee; Katarina Persson; Bo Holmqvist; Dazhi Zhao; Vitaliy Shtutin; Huan Huang; Louis M Weiss; Fabiana S Machado; Stephen M Factor; John Chan; Herbert B Tanowitz; Linda A Jelicks
Journal:  Am J Trop Med Hyg       Date:  2008-11       Impact factor: 2.345

10.  Mexican Trypanosoma cruzi T. cruzi I strains with different degrees of virulence induce diverse humoral and cellular immune responses in a murine experimental infection model.

Authors:  B Espinoza; T Rico; S Sosa; E Oaxaca; A Vizcaino-Castillo; M L Caballero; I Martínez
Journal:  J Biomed Biotechnol       Date:  2010-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.